CS Genetics
Single Cell Genomics at Scale
Cambridge, United Kingdom · Founded 2014 · $161K raised
- Headquarters
- Cambridge
- Employees
- 11–50
- Founded
- 2014
- Business Model
- B2B
- Website
- csgenetics.com
- Total Funding
- $161K
- Last Round
- $161K Series BFeb 2024
- Rounds
- 3
About
CS Genetics is a privately held genomics-technology company developing transformative single-cell analysis tools designed to scale from pilot studies to population genomics. Founded in 2014 by Lucas Edelman and based in Cambridge, England (with a US office in San Diego, California), the company has pioneered a radically new, instrument-free approach to single-cell sequencing that uses chemical biology to index molecules across thousands of cells simultaneously. Its flagship product, the SimpleCell platform, enables complete single-cell RNA-seq experiments in a single day — accelerating discovery, reducing cost per sample, and eliminating batching complexity in a modular, automation-ready format that requires no custom hardware. The SimpleCell 3' Gene Expression Kits, launched in late 2024, are designed to make single-cell transcriptomics accessible to a broader range of research labs. CS Genetics is positioned to serve pharmaceutical, biotech, and academic research customers seeking high-throughput, cost-effective single-cell genomics solutions. Carolina Molecular has been named a certified service provider for the platform. The company is led by CEO Bill Colston, PhD, COO Jay Harger, PhD, and CSO Mike Stubbington, PhD.
Summary
CS Genetics is a Biotech company based in Cambridge, United Kingdom, founded in 2014. It has raised $161K in total across 3 rounds, most recently a $161K Series B round in Feb 2024. Investors include Metaplanet, BroadOak Capital Partners and Mosaic Capital Partners.
Funding History
Feb 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.